Top

BY Clayton Boldt, Ph.D.

Leukemia researchers at The University of Texas MD Anderson Cancer Center, working collaboratively with the Therapeutics Discovery division, have advanced a first-in-class therapeutic antibody into a Phase I clinical trial for patients with high-risk acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and myeloproliferative neoplasms.

The antibody, known as h8F4, is a T-cell receptor (TCR)-like antibody that can kill...

Visualization of the PR1 peptide target on the surface of AML cells.

BY Ron Gilmore

Researchers in MD Anderson’s Leukemia department played central roles in the studies of two drugs, glasdegib and venetoclax, approved in November...

BY Clayton R. Boldt, Ph.D.

MD Anderson’s Moon Shots Program™ was established to bring teams of world-class clinicians and researchers together in order to rapidly advance...

BY Ron Gilmore

Somatic mutations in certain genes may function as a molecular minimal residual disease marker for acute myeloid leukemia (AML), according to a study led by Koichi Takahashi, M.D., assistant professor of Leukemia at MD Anderson. The study showed that clearance of somatic mutation at complete response, particularly in non-preleukemic genes, is associated with significantly better overall survival (OS) and cumulative incidence of relapse...

Koichi Takahashi, M.D., reading a medical report

BY Clayton R. Boldt, Ph.D.

Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) encompass a spectrum of diseases characterized by an overproduction of immature...

BY Clayton Boldt, Ph.D.

Older patients with non-metastatic breast cancer who have been treated modern chemotherapy drugs have a greater risk of secondary acute myeloid...

BY Ron Gilmore

Researchers from MD Anderson Cancer Center presented their latest findings involving drug treatments for blood cancers at the American...

BY Clayton Boldt, Ph.D.

It's been five years since MD Anderson launched its Moon Shots Program™, a collaborative effort to more quickly turn scientific discoveries...

BY Ron Gilmore

Tomas Sandoval was about to become a father for the second time in June 2014, when he was devastated to learn he had non-Hodgkin lymphoma...

BY Ron Gilmore

What if you or a loved one had cancer but were denied access to a research study testing a poten-tially beneficial treatment?

This...